Panzer promoted to CEO of Pharmaca Integrative Pharmacy
BOULDER, Colo. Pharmaca Integrative Pharmacy last week promoted Mark Panzer to the position of CEO after having served as the company’s COO since October 2008.
Barry Perzow, previously CEO, will continue providing leadership and strategic direction to the company he founded in his ongoing role as executive chairman.
Panzer joined Pharmaca after serving as senior EVP and chief marketing officer from 2005 to 2008 at Rite Aid. In this role, he was responsible for merchandising, marketing and logistics for the companies 5,100 stores with revenues of $26 billion.
Panzer holds a master’s of business administration in finance from Loyola University, Chicago and a bachelor’s degree in business administration from Northeastern Illinois University.
Taro files patent infringement suit against three companies
HAWTHORNE, N.Y. An Israeli generic drug maker has sued three other companies, alleging patent infringement.
Taro Pharmaceutical Industries announced Monday that it had filed suit in the U.S. District Court for the District of New Jersey against Synerx Pharma, DPT Labs and Karalex Pharma, alleging infringement of U.S. Patent No. 7,560,445. The patent covers Taro’s Ovide (malathion) lotion in the 0.5% strength, a treatment for head lice.
Taro said the defendants’ generic versions of the drug infringed its patent, and it’s seeking injunctive relief and damages.
News article calls Mylan’s quality control into question; company responds
PITTSBURGH A news article published over the weekend calling generic drug maker Mylan’s manufacturing into question has drawn a response from the company.
The Pittsburgh Post-Gazette reported Sunday that workers at the company’s Morgantown, W.Va., plant overrode drug quality controls required by the government by ignoring and deleting computer warnings of possible drug quality or equipment problems, based on a confidential internal report obtained by the newspaper’s reporters that called it a “pervasive” problem. Normally the warnings, known as “red screens,” require production to halt until a quality-control agent can investigate the matter.
The company responded by saying in a statement Monday that the Post-Gazette article was based on anonymous sources, improperly obtained documents and third-party commentary.
“Our customers and stakeholders can rest assured that whenever there is even the slightest departure from [a standard operating procedure], it will be dealt with immediately and effectively,” the company said in a statement. “This issue had no impact on the quality of our product.”